09:40 AM EDT, 06/10/2026 (MT Newswires) -- Optimi Health ( OPTH ) said Wednesday it has completed its first export of naturally derived psilocybin to the UK to support a planned phase 2 clinical trial for patients with treatment-resistant depression.

The pharmaceutical company said the shipment includes psilocybin biomass and finished 5mg psilocybin capsules.

Price: 4.92, Change: +0.06, Percent Change: +1.19